ArticleFrontiers in oncology2026
Global, regional, and national burden of ovarian cancer and uterine cancer attributable to high BMI, 1990-2021: analysis of data from the global burden of disease study 2021.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High body mass index (BMI) has been identified as a critical factor contributing to the occurrence of ovarian cancer and uterine cancer. This study intended to analyze the global epidemiological trends of ovarian cancer and uterine cancer attributable to high BMI. Methods: Data on early-onset (<50 years old) and late-onset (≥50 years old) ovarian cancer and uterine cancer attributable to high BMI from 1990 to 2021 were extracted from the Global Burden of Disease (GBD) 2021. Mortality, disability-adjusted life-years (DALYs), and average annual percentage change (AAPC) were applied to assess the disease burden. Future trends in mortality and DALYs were projected using the Bayesian age-period-cohort analysis. Results: From 1990 to 2021, the DALYs of early-onset and late-onset ovarian cancer and uterine cancer attributable to high BMI all showed an upward trend, with AAPCs of 1.363 (95%CI: 1.336 to 1.400), 0.405 (95%CI: 0.382 to 0.431), 0.560 (95%CI: 0.490 to 0.637), and 0.300 (95%CI: 0.254 to 0.342), respectively. The mortality outcomes for ovarian cancer and uterine cancer were similar to those observed in DALYs. The age-standardized rates of mortality and DALYs for late-onset ovarian cancer and uterine cancer were significantly higher than those for their early-onset cases. Among regions of different socio-demographic index (SDI), the mortality and DALYs of early-onset and late-onset ovarian cancer exhibited a declining trend in high-SDI regions, while they showed an increasing trend in other SDI regions. For uterine cancer, the mortality and DALYs presented a downward trend in high-middle-SDI regions. Furthermore, the mortality and DALYs for ovarian cancer and uterine cancer are projected to continue rising from 2022 to 2050. Conclusions: The global burden of early-onset and late-onset ovarian cancer and uterine cancer attributable to high BMI has shown an upward trend from 1990 to 2021 and is projected to continue rising in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.